Nivolumab for Non-Small Cell Lung Cancer
This trial is testing if using immunotherapy before and after surgery can prolong event-free survival for people with early stage non-small cell lung cancer.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
In how many different places is this experiment being done today?
"This clinical trial has 19 active sites, which are enrolling patients. These locations include Augusta University in Augusta, Georgia, Northside Hospital in Atlanta, Illinois, and Northwestern University in Chicago, Pennsylvania."
Has Nivolumab received government approval for medical use?
"Nivolumab has been studied in multiple Phase 3 trials, meaning there is some data supporting efficacy and multiple rounds of data supporting safety. Our team at Power estimates the safety of Nivolumab to be a 3 on a scale from 1 to 3."
How large is the sample size for this research project?
"In order to run this clinical trial, 452 patients that fit the pre-determined inclusion criteria are needed. The patients can travel to multiple locations, such as Augusta University in Augusta, Georgia and Northside Hospital in Atlanta, Illinois, in order to participate."
For what purpose is Nivolumab most commonly prescribed?
"Nivolumab is an effective treatment for neoplasm metastasis, metastatic ureter urothelial carcinoma, and metastatic hepatocellular carcinoma."
Are there other similar tests that have been done using Nivolumab?
"Nivolumab was first studied in 1997 and, as of now, there have been 21274 completed trials. There are 2463 active studies recruiting patients with many of these centred in Augusta, Georgia."
Are we currently enrolling people for this research project?
"That is correct. The aforementioned website has this trial listed as currently looking for 452 individuals to participate. These 16 sites have been collecting data since November 5th, 2019."